With all due respect I call BS on the fact that you would have the audacity to compare Imugene with stocks such as Celularity and Precision. if IMU's stock couldn't perform on the Nasdaq with the value proposition it has, the ongoing results in the previous year's and the FDA IND's it has obtained I'd be dumbfounded. Do some more research on Imugene's pipeline in contrast to these companies and I'm confident you'll reach a different conclusion.
But therein may lie a greater problem. Half the market may think like you.
Why IMU is a multi multi bagger, page-16179
-
- There are more pages in this discussion • 9,256 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
